PSY42 Patient-Reported Outcome (PRO) Instrument for Detection of Peripheral Neuropathy (PN) in Patients With Multiple Myeloma (MM): The FACT/GOG-Ntx  by Choi, S. et al.
ropathy, 16 HIV-associated neuropathy and 8 post herpetic neuralgia) with amean
age of 60.3(12.3) years and an even gender distribution were interviewed. Patient
treatment experience ranged from anticonvulsants (73%), antidepressants (34%),
opioids (25%), to topical medications (41%). Pain descriptors and treatment attri-
butes were similar across the three NP groups. Pain relief was judged the most
important treatment attribute, followed by ability to do activities. Sleep improve-
ment was another important attribute. Activity limitations and QL were perceived
as too broad and unspecific, andwere split into 3 concepts each (self care, daily and
physical activities; sleep, emotions, and social function). A 7-day recall period was
introduced. The item stem and response options were made consistent, and a
baseline and follow-up questionnaires were developed (except for the satisfaction
items) to enable monitoring onset of treatment benefit and change over time.
CONCLUSIONS: The content validity of the revised SAT was improved by the qual-
itative research, and NP treatment benefits are reflected in amore consistent fash-
ion by the changes. Baseline and follow-up versions make assessments of change
over time possible.
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OBJECTIVES: The National Institutes of Health (NIH) roadmap project: Patient-
Reported OutcomesMeasurement Information System® (PROMIS®) has developed
a series of large calibrated item banks and a computer adaptive testing (CAT) sys-
tem, allowing for efficient and robust assessment of a wide range of health out-
comes. This study seeks to assess the performance of PROMIS-CAT by evaluating
the frequency and sequence of items administered in a clinical trial. METHODS:
This was a 13-week randomized, double-blind, placebo-controlled drug switch
study in fibromyalgia patients. PROMIS-CAT assessmentswere scheduled for three
study visits using AssessmentCenterSM (v.1.0 item banks with standard CAT pa-
rameters) for the four following domains: Fatigue; Physical Function (PF); Satisfac-
tionwithDiscretionary Social Activity (DSA); andWakeDisturbance (WD). PROMIS-
CAT administers those items which are most informative to assess individual
patients based on their prior responses and their latent trait score. Findings were
summarized via descriptive statistics.RESULTS:A total of 107 randomized patients
completed at least one PROMIS-CAT assessment. Each PROMIS-CAT instrument
was administered 256 times. Pooled analysis of all administrations determined the
following observations: 36 of 95 (38%) Fatigue items were administered (including
4-items administered 50% of the time). 30/124 (24%) PF items were administered
(3-items 50% of the time). All items from the DSA (12-items) and WD (16-items)
banks were administered (4-items 50% of the time each). There were 41 unique
item sequences for Fatigue, 48 for PF, 20 for DSA and 21 for WD. DSA andWD each
had one sequence of items that was used in over half of the assessments.
CONCLUSIONS: PROMIS-CAT administered a subset of items from the full item
banks which are most informative in assessing individual patients with fibromy-
algia. Fewer than half the items from the Fatigue and Physical Function item banks
were administered. DSAandWDhad all items administered and fewer unique item
sequences.
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OBJECTIVES: Peripheral Neuropathy (PN) is a key side effect of several MM thera-
pies, including bortezomib. PRO instruments, such as the FACT/GOG-Ntx (v4.0)
11-item ‘Additional Concerns’ scale, may be helpful for early identification of pa-
tients at risk or with subclinical evolving PN. This analysis evaluated its ability to
predict PN after examining correlations between patient-reported FACT/GOG-Ntx
and physician-documented clinical PN (NCI-CTCAE v3.0) using data from a phase 3
trial. METHODS: In the VISTA study, 682 untreated, transplant-ineligible MM pa-
tients (median age 71 years) received up to nine 6-week cycles of bortezomib-
melphalan-prednisone (VMP) orMP, and completed FACT/GOG-Ntx v4.0 each cycle
(day 1). Correlations between clinical PN and FACT/GOG-Ntx sensory subscale
(items 1-4) were determined using Pearson correlation coefficients. A logistic re-
gression model evaluated detection accuracy; receiver operating characteristic
(ROC) curve analyses were conducted based on logistic regression results for pre-
diction of clinical PN by FACT/GOG-Ntx sensory subscale at cycles 1-5. Area under
ROC curve (AUC) is ameasure of accuracy; AUC should be.50 for an instrument to
be useful. RESULTS: Pearson correlation coefficient was 0.43, 0.44, and 0.47 at cy-
cles 3, 4, and 5, respectively, indicating some association between FACT/GOG-Ntx
and clinical PN. Using ROC curve analysis for prediction of grade 1, 2, 3, and 4
PN, respectively, AUCs were: .52, .53, .57, and .63 at cycle 1; .63, .64, .63, and .85 at
cycle 2; and .71, .75, .76, and .96 at cycle 3. At cycle 4, AUCswere .77, .79, and .75, and
at cycle 5 were .78, .80, and .79 for grade 1, 2, and 3 PN, respectively.
CONCLUSIONS: FACT/GOG-Ntx sensory subscale demonstrated substantial pre-
dictive utility for early detection of clinical PN. FACT/GOG-Ntx could be a useful
PRO tool for early bortezomib-associated PN detection and management. Similar
analyses of additional phase 2 (SUMMIT) and 3 (APEX) studies are planned.
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OBJECTIVES: To examine patient perspectives on perceived value of medications
used in moderate-to-severe psoriasis in the United States.METHODS: Online sur-
veys and patient focus groups were conducted from a nationally representative
psoriasis patient panel was conducted in April 2010. Respondents, aged 18 years
old, were grouped as mild and moderate-to-severe psoriasis. Participants were
asked to rate PsO severity based on palm rule where one palm is considered as
covering 1% body surface area (BSA). Participants were also asked about time to
diagnosis, treatment history, monthly out-of-pocket treatment costs, and value of
treatments. RESULTS: Of the 1013 participants, 50% were male, and mean age was
49 years. Psoriasis disease severity was reported by 32% (n321) as mild and 68%
(n692) as moderate-to-severe. Annual household income ranging from $25-75K
was reported by 40% of participants. Over 70% had been diagnosed with psoriasis
for 5years. Among those currently receiving prescription or over-the-counter
psoriasis treatment (n795), approximately one-third (mild37%, moderate-se-
vere35%) reported very good/excellent value for their PsO treatment as compared
to good (33% and 31%, respectively), fair (24%, 27%), and poor (6%, 8%). Patients
receiving biologic or disease modifying anti-rheumatic drugs (DMARD) (47% and
52%, respectively) rated the value of their treatment as very good/excellent com-
pared to other treatments, including light therapy. Those with out-of-pocket costs
$50 (mild88%, moderate-severe71%) were more likely to perceive their treat-
ment is of very good/excellent value. CONCLUSIONS: The majority of participants
in this survey suffered from long-standing moderate-to-severe psoriasis. The ma-
jority of participants, with the exception of those using biologics or DMARDs, per-
ceived they weren’t receiving good value for their psoriasis treatments. Partici-
pants with out-of-pocket medication costs less than $50/month perceived higher
treatment value.
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OBJECTIVES: To examine characteristics of individuals with moderate-to-severe
psoriasis in a US nationally representative population. METHODS: A nationally
representative patient panel was surveyed in April 2010 to recruit adult (18 years
old) psoriasis patients of all severity levels. Participants were asked about severity
of disease, affected locations, time to diagnosis, and treatment history. Participants
rated disease severity based on “palm rule”, where the palm of the hand was used
to estimate 1% body surface area (BSA). RESULTS: A total of 1013 patients re-
sponded to the survey. Fifty percent were female, 32% (n321) had mild and 68%
(n692) hadmoderate-to-severe psoriasis. Patient ages in yearswere distributed as
follows: 30%  40; 45% 40-59 and 25%  60. Over 70% of both mild and moderate-
severe severity patients were diagnosed 5 years ago. Among the moderate-to-
severe group, the top three body locations affected were elbows and/or arms (70%),
scalp (69%), and knees and/or legs (64%). 68% (n471) characterized their psoriasis
asmoderate-to-severe at time of diagnosis and 78% (n540) asmoderate-to-severe
before starting current treatment. Using the rule of palm, 70% reported 3-10% BSA
at time of diagnosis, 72% before starting current treatment, and 45% currently.
Prescription topical and other topical treatmentsweremost commonly used (48.8%
and 32.4% respectively), followed by over-the-counter (OTC) medications (25%),
prescription oral (14.6%), 12.6% biologics, and phototherapy (7.4%). 20% of patients
(n139) reported as not currently treating their psoriasis. CONCLUSIONS: Psoriasis
is a chronic condition affecting all age groups. The majority of patients are being
diagnosed when the disease has progressed to moderate or severe stage. Individ-
uals try various treatments to manage their psoriasis ranging from OTC medica-
tions to biologic treatments. Patient education and awareness programs, and
shared-decision making aides may help with early diagnosis of psoriasis and en-
able optimal treatment.
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OBJECTIVES: To examine patient insights and perspectives among individuals
with psoriasis using novel multi-discriminate analysis (MDA). METHODS: Patient
focus groups and online surveys were conducted from a nationally representative
psoriasis patient panel from 2Q-4Q2010. Participantswere asked about treatments,
impact on daily life, accessibility and affordability, and knowledge about psoriasis.
Key audio excerpts from focus group transcripts were used for moment-to-mo-
ment analysis in an online survey of psoriasis patients 18 years old. Cluster
analysis was used to segment patients into mutually exclusive patient groups
based patient characteristics and preferences. MDA was performed to identify key
points of divergence in perspective/opinion on the focus group dialogue. RESULTS:
Of the 1013 respondents, 50% were female, 32% (n321) had mild and 68% (n692)
hadmoderate-to-severe psoriasis. Patient ages in yearswere distributed as follows:
30%  40; 45% 40-59 and 25%  60. Patient preference for biologic treatments for
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